Infrastructure that channels research investment into the pipeline.
Infrastructure that channels research investment into the pipeline, with revenue flowing back to Syngenis.
More access, less risk.
Infrastructure that channels research investment into the pipeline.
Syngenis provides infrastructure and access support to independently managed, licensed funds that channel third party investment into RNA and DNA research. Each program sits in its own dedicated vehicle, keeping early stage research funded while Syngenis captures revenue through manufacturing, analytics, design and intellectual property services at each step.
How it is structured.
- Each program is held in a dedicated vehicle, so research cost sits outside the Syngenis balance sheet.
- The scientist or inventor keeps a direct stake, aligning incentives through to commercialisation.
- Every program uses Syngenis for manufacture, analytics, design and IP, so revenue flows back at each step.
General information only.
This page is strictly informational. It describes the role of the Fund pillar within the Syngenis platform and is not an offer, invitation, solicitation, valuation or recommendation in relation to any financial product. All wording is subject to legal review.
Ready to work with an integrated life sciences company?
Talk to our team about your program, from candidate design to trial ready material.
One engine, working across the whole business.
Syngenis One (AI Discovery)
Design RNA and DNA candidates from target to synthesis ready oligo in one workflow.
Manufacturing
Australia's only commercial RNA facility. Custom oligonucleotides, ordered through Syngenis One.
Research and Diagnostics
AI led therapeutic programs and an aptamer based diagnostics pipeline.
Clinical
A specialist nucleic acid CRO with in silico trial modelling.
Life Care
Consumer genomics at a mass market price.
Fund
Infrastructure that channels research investment into the pipeline.